Informations générales (source: ClinicalTrials.gov)
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials
Interventional
N/A
Institut Bergonié (Voir sur ClinicalTrials)
décembre 2015
décembre 2029
16 septembre 2025
This is a biology driven, monocentric study designed to identify actionable molecular
alterations in cancer patients with advanced disease.
In this trial, high throughput analysis will be carried out using next generation
sequencing, and immunological profiling.
Patients included in the BIP study and for whom a targetable genomic alteration had been
identified might be subsequently included in an early phase trials running at Institut
Bergonie or another French hospital.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Hospitalier de la Côte Basque - 64000 - Bayonne - France | Thomas GRELLETY, MD | Contact (sur clinicalTrials) | |||
| Institut Bergonie - 33076 - Bordeaux - France | Antoine ITALIANO, MD, PhD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Eugène Marquis - Rennes - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier de Pau - 64000 - Pau - France | Patrick ALDO RENAULT | Contact (sur clinicalTrials) | |||
| Clinique Marzet - 64000 - Pau - France | Sylvestre LE MOULEC | Contact (sur clinicalTrials) | |||
| Clinique Tivoli-Ducos - 33000 - Bordeaux - France | Delphine GARBAY, MD | Contact (sur clinicalTrials) | |||
| Polyclinique Bordeaux Nord Aquitaine - 33077 - Bordeaux - France | Camille MAZZA, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Age ≥ 18 years,
2. Histology: solid malignant tumor or hematological malignancy,
3. Deleted MSA9
4. Deleted MSA9,
5. Deleted MSA9,
6. Deleted MSA9,
7. Patient with a social security in compliance with the French law relating to
biomedical research (Article L.1121-11 of French Public Health Code),
8. Voluntary signed and dated written informed consent prior to any study specific
procedure.
1. Age ≥ 18 years,
2. Histology: solid malignant tumor or hematological malignancy,
3. Deleted MSA9
4. Deleted MSA9,
5. Deleted MSA9,
6. Deleted MSA9,
7. Patient with a social security in compliance with the French law relating to
biomedical research (Article L.1121-11 of French Public Health Code),
8. Voluntary signed and dated written informed consent prior to any study specific
procedure.
1. Deleted MSA9
2. Deleted MSA9
3. Deleted MSA9
4. Deleted MSA9
5. Deleted MSA9
6. Deleted MSA9
7. Deleted MSA9
8. Deleted MSA9
9. Individuals deprived of liberty or placed under guardianship
10. Pregnant or breast feeding women,
11. Previous enrolment in the present study.